This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.